バイオバンクの世界市場予測2016-2026

◆英語タイトル:Biobanking Market Forecasts 2016-2026
◆商品コード:VGAIN60628
◆発行会社(調査会社):visiongain
◆発行日:2016年4月
◆ページ数:249
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥291,854見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥437,854見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥729,854見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、バイオバンクの世界市場について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2.バイオバンクとその応用の概要

3. 医薬品用バイオバンク: 世界市場 2015-2026

4. 研究目的用バイオバンク

5. 将来の治療目的に使用されるステムセルバンク

6. 主要国市場 2015-2026

7. バイオバンク技術: バイオバンクに関連するシステム、ソフトウェア、消耗品、サービス

8. バイオバンク市場における主要企業

9. バイオバンク市場の定性分析 2015-2026

10. 調査インタビュー

11. 研究・分析の結論
【レポートの概要】

Biobanks – How to Discover Trends, R&D and Sales Forecasts from 2016, Helping Your Influence
Are you interested in the future of medical biobanking? If so, you can now gain technological and commercial predictions from 2016. That way you stay ahead for data, benefiting your authority. There explore trends in research and development, results, opportunities and revenue forecasts.

That new study by visiongain shows you what is possible for biobanking and associated technology for human healthcare. Avoid missing out. Instead find sales potentials for that biomedical industry and market, discovering expected trends, progress and financial gains.

Biobank services and technology exert great influence on drug discovery and development. That importance increases from 2016. See what the future holds.
Potential of those biorepository technologies and storage facilities
In medical research those biostorage systems form an important resource. They support fields including genomics and personalised medicine, letting companies store and use samples.

Our report’s purpose is showing you the commercial potential in storing human biological samples for use in research and therapies, including conserving stem cells.

Please read on to explore those technologies and services for human medicine, finding what influences that market and seeing predicted revenue.

Forecasts and other information showing lucrative possibilities for biorepositories
Our study gives sales predictions to 2026 at overall world, submarket and national level. You also get sample unit predictions. For biosample and biospecimen storage, especially for pharmaceutical R&D, you investigate where applications, needs, demand and money lie.

Why struggle to find information or miss data you need on medical biopreservation? Besides revenue forecasting, our new analysis shows you results, growth rates and market shares.

There you explore those technologies for medical R&D – especially applications suiting drug companies. Our new report gives you 72 tables, 74 charts and three interviews with authorities in that field. Discover, from 2016, the potential of biobanks.

Forecasting of that world market and its segments – you find commercial prospects
See in our report overall world revenue to 2026, with discussions, for storing human cell, tissue and fluid samples.

That way you can help your research, analyses and decisions on storage of human biological samples (HBS). As someone with authority, benefit your reputation for technological and commercial insight.

In particular find individual revenue predictions to 2026 for nine submarkets at world level:
• Biobanking for research
• Biobanking for therapeutic uses.

There you find biobanking revenue forecasting to 2026 by research application:
• Human tissues – also with sub-forecasts for public sector and commercial uses
• Stem cells
• Other biological sample banking applications – inc. DNA and body fluids.

And our analysis predicts stem cell banking revenues to 2026 for therapeutic uses:
• Umbilical cord stem cell banking
• Adult stem cell banking.

You also get forecasts to 2026 for the number of samples banked for research and therapeutic applications.

In our study you assess outlooks for sales expansion, hearing where you could gain. That work explores competition and demand, showing technological and commercial possibilities.

So hear what is happening. You also investigate geographical revenue potentials.

Biostorage needs in leading national markets – what outlooks for demand, sales and capacity?
In developed and developing countries, opportunities for companies providing biorepository facilities, products, services, consumables and technology will expand from 2016.

Our analyses show you individual revenue forecasts to 2026 for 12 leading national biobanking markets:
• The US
• Japan
• Germany, France, the UK, Italy, Spain and the Netherlands
• Brazil, Russia, India and China.

There discover countries with highest sales, demand and potential expansion of usage and revenues. That way you investigate progress, needs, opportunities and competitors. And you see the gains possible, finding how you could expand your business.

Also what events, challenges and advances in technology affect biorepositories?

Forces influencing suppliers and users of those biomedical resources and libraries
Our new study explores issues, events and contributions affecting that industry and market from 2016, including these influences:
• Guidelines, research and medical ethics, standards (e.g. GLP), legislation, regulations and governmental funding for that biopreservation, inc. HIPAA amendments
• Systems for cryopreservation, biobank networks and biobanking infrastructure
• Facilities, freezers, operations software, consumables and services
• Biobanking in research, drug discovery and development, inc. biomarkers and personalised medicine
• Uses in therapeutics, clinical trials and genome-wide association studies (GWAS).

And you explore these forces, among others:
• Numbers and geographical distribution of biobanks
• Umbilical cord blood banking and induced pluripotent stem cells (iPSCs)
• RFID, tagging technology and laboratory information management systems (LIMS)
• Technologies and services aiding genetic epidemiology studies and understanding of disease pathways
• Automated liquid handling systems, and automation in DNA isolation
• Biobanking services – sample storage, tracking, management and transport of human biological samples.

That way you find what stimulates and restrains organisations performing and helping that biosample preservation, affecting their results and those of biobank clients.

Technologies and applications – top organisations and 2020 market value
What future sales results are possible? Our study predicts that the world biobanking market will generate $27.5bn in 2020. Rising demand for biobanked samples for use by pharmaceutical companies in preclinical research most stimulates biobanking revenues.

Our analysis shows activities of biobanks, including these organisations:
• Stemgent
• Biopta
• BioServe
• Coriell Institute for Medical Research
• Cord Blood America
• Cryo-Cell International.

And other companies, including these:
• China Cord Blood Corp
• LifebankUSA
• ViaCord
• Cord Blood Registry
• Biogenea Pharmaceuticals
• StemLife
• Caladrius Biosciences.

That way you assess competitors and developments. Our analysis includes interviews with Fidelis Research, Bulgaria, 3C-R, France, and the UK ME/CFS Biobank Project. So avoid missing out in knowledge. See what other authorities say and do, helping your work.

Five ways Biobanking Market Forecasts 2016-2026 helps your work
In these five main ways, our new investigation helps you get recognition for insight, saving time and benefiting your authority:
• Revenues for biobanking, to 2026, at world level and for 9 submarkets – explore prospects for design, production, sales, marketing, demand and spending
• Forecasts, to 2026, for 12 countries in the Americas, Europe and Asia – assess developed and developing national markets for demand and predicted revenues
• Prospects for established organisations, rising companies and new entrants – examine service and product portfolios, results, strategies and outlooks for success
• Analysis of what stimulates and restrains that industry’s participants – investigate challenges, strengths and competition affecting organisations’ results
• Interviews with organisations – discover what authorities in that field say and do, helping you stay ahead in knowledge to help your work.

That report, by visiongain’s UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. You get data leading companies depend on.

Information there found nowhere else, helping your searches, analyses and planning
An off-the-shelf report cannot answer every question, though our work explains that industry’s structures, outlooks and potentials.

Our analyses give independent data. There you get competitive intelligence found only in that study, finding where progress, money and opportunities lie. See what the future holds.

With that research and analysis you are less likely to fall behind in knowledge or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions and presentations, helping you gain advantages and recognition.

Trying our study now lets you discover biobanking opportunities and predictions
Stay ahead in data. Our new investigation is for everyone analysing medical biotechnology and pharmaceutical R&D. For storing biological samples you see trends, opportunities and revenue predictions. So avoid missing out – please get our new report here now.

【レポートの目次】

1. Report Overview
1.1 Biobanking for Medicine: World Market Review 2015 and Global Segmentation
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to Biobanking and its Applications
2.1 Defining the Human Tissue Banking Market for the Scope of this Report
2.2 The Stem Cell Banking Market – Our Breakdown
2.3 What is Biobanking?
2.4 Main Features of Biobanks
2.5 What Processes are Involved in Biobanking?
2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
2.6.1 Volunteer Group: General vs. Disease Population
2.6.2 Ownership Structure: Public vs. Private
2.7 The Guidelines and Standards for Biobanking
2.8 Laws and Regulations for Biobank-Based Research
2.8.1 HIPAA Amendments
2.9 Biobanking and the Pharmaceutical Industry
2.9.1 Biobanking in Research, Drug Discovery and Development
2.9.1.1 Biobanking – Facilitates Genetic Epidemiology Studies
2.9.1.2 Novel Drug Discovery through Better Understanding of Disease Pathways
2.9.1.3 Biomarker Discovery in Drug Development
2.9.2 Biobanking for Therapeutic Purposes
2.9.3 Biobanking in Clinical Trials

3. Biobanking for Medicine: World Market 2015 to 2026
3.1 The World Biobanking for Medicine Market in 2015
3.2 Biobanking for Medicine: Research vs. Therapeutics in 2020 and 2026
3.3 World Biobanking for Medicine Market: Overarching Revenue Forecast 2015 to 2026
3.4 Biobanks Stored More Than 1.4 Billion Specimens in 2015
3.5 The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2015 to 2026
3.6 Biobanking for Research: Mostly Non-Profit
3.6.1 Biobanking for Research: Revenue Forecast 2015 to 2026
3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2015 to 2026
3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2015 to 2026

4. Biobanking for Research Purposes
4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2015
4.2 Biobanking for Research in 2020 and 2026: Comparison by Tissue Type
4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2015 to 2026
4.4 How Many Specimens are Biobanked for Research?
4.5 The Human Tissue Banking Market for Research in 2015
4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2015 to 2026
4.7 The Human Tissue Banking Market: Commercial vs. Public Sectors
4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2015 to 2026
4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2015 to 2026
4.8 The Stem Cell Banking Market for Research in 2015
4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2015 to 2026
4.9.1 R&D- Growing Interest Towards iPSCs
4.10 Banking of Other Biologics Specimens for Research in 2015
4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2015 to 2026

5. Stem Cell Banking for Future Therapeutic Use
5.1 Stem Cell Banking for Therapeutic Use in 2015: A Breakdown by Stem Cell Type
5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2020 and 2026
5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
5.4 How Many Stem Cells Are Biobanked Each Year?
5.5 The Umbilical Cord Blood Banking Market in 2015
5.5.1 Private vs. Public Cord Blood Banking
5.5.2 Umbilical Cord Blood Banking: The Controversies
5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2015 to 2026
5.7 The Adult Stem Cell Banking Market in 2015
5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2015 to 2026

6. Leading National Markets 2015 to 2026
6.1 The Geographical Footprint of Biobanking
6.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
6.1.2 Biobanks in the US: A Fragmented Picture
6.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
6.2 Biobanking for Medicine: The US Led the Way in 2015
6.3 The Leading National Markets: Grouped Revenue Forecasts 2015 to 2026
6.4 How Will Regional Market Shares Change to 2026?
6.5 The US Biobanking Market 2015 to 2026: Diversifying and Expanding
6.6 The Top European Biobanking Markets 2015 to 2026: Leading the Way in Biobanking Infrastructure
6.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
6.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
6.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
6.6.4 UK: Limited Presence of Biobanking Networks
6.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
6.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
6.7 The Japanese Biobanking Market 2015 to 2026: A High Level of Government Investment Drives Growth
6.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2015 and 2026
6.8.1 The Chinese Biobanking Market 2015 to 2026: The High Rate of Growth Will Continue
6.8.2 The Indian Biobanking Market 2015 to 2026: Set to Become the Leading Market for Private Stem Cell Banking?
6.8.3 The Brazilian Biobanking Market 2015 to 2026: Will New Regulations Drive or Restrain the Market?
6.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2015 to 2026?

7. Technology for Biobanking: Systems, Software, Consumables and Services Associated with Biobanking
7.1 The Biobanking-Associated Market: Overview
7.2 Systems Technology: Fully Automated Handling
7.2.1 Automated Liquid Handling Systems
7.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
7.2.3 Automated DNA Isolation
7.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
7.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
7.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
7.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
7.3.4 Automated Storage and Retrieval Systems: Essential Technology
7.3.5 RFID and Tagging Technology: Advantages over Barcodes
7.4 Software for Biobanks
7.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
7.4.2 LIMS Functions
7.5 Consumables: High Quality Required for Effective Sample Management
7.5.1 Addressing Sample Storage and Tracking Issues
7.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

8. Leading Companies in the Biobanking Market
8.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
8.2 Commercial Biobanks for Research Purposes in 2015
8.2.1 Tissue Solutions: A Virtual Biobank with a Global Presence
8.2.1.1 An Overview of the Products and Services Offered by Tissue Solutions
8.2.1.2 Banked Samples Occur in Many Formats
8.2.1.3 Prospective Tissue Collection for Hard-to-Find Samples
8.2.1.4 Fresh Samples from Surgical Resections are in High Demand
8.2.1.5 Freshly Isolated Human Cells are a Valuable Research Tool
8.2.1.6 FDA/ EMA Panel of Normal Tissues
8.2.1.7 Strengths, Capabilities and the Future Outlook for Tissue Solutions
8.2.2 Asterand Bioscience is now Part of Stemgent
8.2.2.1 Asterand’s Products and Services: XpressBANK, BioSpoke and PhaseZERO
8.2.2.2 The Future Outlook for Asterand
8.2.3 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
8.2.3.1 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
8.2.3.2 The First Catalogue of Assays Based on Human Functional Tissues
8.2.3.3 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
8.2.4 BioServe: One of the World’s Largest Commercial Biorepositories
8.2.4.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
8.2.4.2 The Future Outlook for BioServe
8.2.5 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
8.2.5.1 Features of and Recent Developments at Coriell Biobank
8.2.5.2 Future Outlook for the Coriell Biobank
8.3 Prominent Biobanks for Therapeutic Use in 2015
8.3.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
8.3.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
8.3.3 Cryo-Save’s Educational Programme Benefits Company’s Growth
8.3.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
8.3.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
8.3.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
8.3.7 Cord Blood Registry: The World’s Largest Newborn Stem Cell Company Will Be Promoted By New Parent Company
8.3.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
8.3.9 StemLife is Reportedly Facing Challenges Due to Government Regulations in Malaysia
8.3.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
8.3.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
8.3.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

9. Qualitative Analysis of the Biobanking Market 2015 to 2026
9.1 Industry Trends
9.1.1 The Growing Demand for Biobank Resources for Research
9.1.2 The Establishment of Biobanking Networks
9.1.2.1 BBMRI: The Most Extensive Biobank Network
9.1.3 Virtual Biobanks: Connecting a Fragmented Industry
9.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
9.1.5 Automated Biobanking Has Become Imperative
9.1.6 Increasing Uptake of LIMS
9.1.7 Green Banking – Becoming More Energy Efficient
9.2 The Strengths and Weaknesses of the Biobanking Market in 2015
9.2.1 HBS are Valuable Resources for R&D
9.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
9.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
9.2.4 The Effect of Big Data on Biobanking
9.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
9.2.6 Biobanks are Fragmented and Uncoordinated
9.2.7 Lack of Standardisation is a Weakness of the Industry
9.2.8 Lack of Public Awareness Limits Number of Donors
9.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
9.3 Opportunities and Threats Facing the Biobanking Market, 2015 to 2026
9.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
9.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
9.3.3 Biobanking Networks as a Basis for Personalised Medicine
9.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
9.3.5 Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
9.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
9.3.7 Limitations Surrounding Informed Consent
9.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2015 to 2026

10. Research Interviews
10.1 Mr Veselin D. Stefanov, MBA, General Manager, Fidelis Research, Bulgaria
10.1.1 Fidelis Research – Specialists in Human Tissue Procurement With a Strong Network of Partners
10.1.2 Challenges in Tissue Procurement Stem from a Lack of Legislation
10.1.3 Lack of Standardisation Causing Decreased Demand for Biobanked Tissues
10.1.4 Significant Therapeutic Areas of Demand
10.1.5 Essential Qualities for a Successful Tissue Procurement Service
10.1.6 The Impact of Trends in Biobanking
10.2 Dr Jeanne-Hélène di Donato, 3C-R, France
10.2.1 French Biobanks – a Network of Specialized Biobanks
10.2.2 Biobanking Management –Promoting Scientific Value of Collections
10.2.3 Harmonization – Scientific Valorisation
10.2.4 Bioethical – Diverse Views and Policies on Consent
10.2.5 Broad Consent –Is This the Best Option?
10.2.6 3C-R – Services and Solutions for Biobanks
10.3 Dr Luis Nacul and Dr Eliana Lacerda, UK ME/CFS Biobank Project
10.3.1 UK ME/CFS Biobank – Objectives and Activities
10.3.2 Biobank Resource – Available for External Researchers in August 2015
10.3.3 Main Issue – Sustainability
10.3.4 Unmet Needs – Awareness from Government and General Public

11. Conclusions from Our Research and Analysis
11.1 World Biobanking Market 2015 to 2026: High Revenue Growth Predicted
11.2 Biobanking for Research 2015 to 2026: The Value of Biobanked Specimens is Increasingly Recognised
11.3 Biobanking for Therapeutic Use 2015 to 2026: Rapid Expansion in Adult Stem Cell Banking
11.4 The Leading National Markets: High Sales Growth Worldwide
11.5 Current and Future Trends in Biobanking
11.5.1 Increasing Demand for Biobanked Samples – Increasing Revenue
11.5.2 Improving Biobanking Infrastructure – Growth Driver and a Need for Strategic Planning for Sustainability
11.5.3 Marked Challenges, but Opportunities for Expansion

Table 2.1 Prominent Population-Based Biobanks, 2016
Table 2.2 Prominent Disease-Based Biobanks, 2014
Table 2.3 Guidelines and Recommendations for Biobanks, 2014
Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2016
Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2014
Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2015
Table 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
Table 3.3 Biobanking for Medicine: Overall World Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 3.4 Number of Samples Stored in Biobanks by Purpose: Overall World Forecast, Number of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
Table 3.5 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 3.6 Biobanking Market for Research Forecast: Revenue ($bn) Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 3.7 Biobanking for Therapeutic Use Forecast: Revenue ($bn) Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.1 The Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2015
Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
Table 4.3 Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.4 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.5 Human Tissue Banking Market Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Shares (%), 2015, 2020 and 2026
Table 4.7 The Human Tissue Banking Market Forecasts by Subsector: Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.8 Commercial Human Tissue Banking Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.9 Prominent Commercial Human Tissue Banks, 2014
Table 4.10 Public Sector Human Tissue Banking Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.11 Prominent Public-Funded Human Tissue Banks, 2014
Table 4.12 The Stem Cell Banking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2014
Table 4.14 Banking of Other Biologic Specimens for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2014
Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Revenues ($bn) and Market Shares (%), 2015
Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Shares (%), 2020 and 2026
Table 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 5.4 The Number of Stem Cell Samples Banked for Therapeutic Use: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2015 to 2026
Table 5.5 Prominent Public and Private Cord Blood Banks, 2014
Table 5.6 The Umbilical Cord Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2014
Table 5.8 The Adult Stem Cell Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.1 Breakdown of BBMRI Network Directory Members by Country, 2016
Table 6.2 The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2015
Table 6.3 Leading National Markets Grouped Forecasts Revenue ($bn), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.4 Leading National Markets: Comparison of Market Shares (%), 2015, 2020 and 2026
Table 6.5 Biobanking for Medicine in the US Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.6 The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.7 Examples of Biobanking Initiatives Funded by the European Commission, 2016
Table 6.8 The German Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.9 The French Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.10 The Italian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.11 The UK Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.12 The Spanish Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.13 Prominent Clinical and Population Biobanks in the Netherlands, 2016
Table 6.14 The Netherlands Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.15 The Japanese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.16 The Biobanking Industry in the BRIC Countries Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.17 The Chinese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.18 The Indian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.19 Prominent Research Biobanks in India, 2016
Table 6.20 The Brazilian Biobanking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 6.21 The Russian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2015 to 2026
Table 7.1 Prominent Companies Providing Automated Liquid Handling Technology, 2016
Table 7.2 Prominent Companies Providing Room Temperature Storage Solutions, 2016
Table 7.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80°C), 2016
Table 7.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2014
Table 7.5 Prominent Companies Providing Cryogenic Storage Solutions, 2016
Table 7.6 Prominent Providers of Automated Biobanking Systems, 2016
Table 7.7 Major Vendors in the LIMS Market, 2016
Table 7.8 Prominent Vendors of Consumables for Biobanking, 2016
Table 7.9 Prominent Biorepository Service Providers, 2016
Table 8.1 Prominent Players in the Biobanking Industry for Research, 2016
Table 8.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2016
Table 8.3 China Cord Blood Corp: Revenue ($m), Total Units Stored for Subscribers, and No. Of New Subscribers, 2013 to 2015
Table 8.4 StemLife: Comparison of Revenue ($m) between 2014 and 2015
Table 9.1 Strengths and Weaknesses of the Biobanking Industry, 2016
Table 9.2 Opportunities and Threats Facing the Biobanking Industry, 2015 to 2026
Table 9.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2015 to 2026

Figure 1.1 Global Biobanking Industry Segmentation Overview, 2016
Figure 2.1 Processes Involved in Biobanking, 2016
Figure 2.2 The Classification of Biobanks, 2016
Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2015
Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2020
Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2026
Figure 3.4 Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2015 to 2026
Figure 3.5 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. of Samples (m), 2015 to 2026
Figure 3.6 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), 2015 to 2026
Figure 3.7 Biobanking Market for Research: Revenue Forecast ($bn), 2015 to 2026
Figure 3.8 Biobanking for Research: Drivers and Restraints, 2015 to 2026
Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2015 to 2026
Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2015 to 2026
Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Shares (%), 2015
Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2020
Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2026
Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2015 to 2026
Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2015 to 2026
Figure 4.6 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2015 to 2026
Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($bn), 2015 to 2026
Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2015 to 2026
Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2015
Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2020
Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2026
Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2015 to 2026
Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($bn), 2015 to 2026
Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2015 to 2026
Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2015 to 2026
Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2015 to 2026
Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2015 to 2026
Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2015 to 2026
Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2015
Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2020
Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2026
Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2015 to 2026
Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2015 to 2026
Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2015 to 2026
Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2015 to 2026
Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2015 to 2026
Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2015 to 2026
Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2015 to 2026
Figure 6.1 The Leading National Biobanking Markets: Market Shares (%), 2015
Figure 6.2 The Leading National Markets: Grouped Revenue Forecasts ($bn), 2015 to 2026
Figure 6.3 The Leading National Markets: Market Shares (%), 2015
Figure 6.4 The Leading National Markets: Market Shares (%), 2020
Figure 6.5 The Leading National Markets: Market Shares (%), 2026
Figure 6.6 Biobanking for Medicine in the US: Revenue Forecast ($bn), 2015 to 2026
Figure 6.7 Driving and Restraining Factors of the US Biobanking Market, 2015 to 2026
Figure 6.8 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2015 to 2026
Figure 6.9 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2015 to 2026
Figure 6.10 The German Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.11 The French Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.12 The Italian Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.13 The UK Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.14 The Spanish Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.15 The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.16 The Japanese Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.17 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2015 to 2026
Figure 6.18 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2015 to 2026
Figure 6.19 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2015 to 2026
Figure 6.20 The Chinese Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 6.21 The Indian Biobanking Industry: Revenue ($bn) Forecast, 2015 to 2026
Figure 6.22 The Brazilian Biobanking Market: Revenue Forecast ($bn), 2015 to 2026
Figure 6.23 The Russian Biobanking Industry: Revenue Forecast ($bn), 2015 to 2026
Figure 7.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2016
Figure 7.2 The Basic Function of LIMS
Figure 8.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2016
Figure 8.2 Business Model: Commercial Banking of Biological Samples, 2016
Figure 8.3 China Cord Blood Corp: Revenue ($m), 2013 to 2015
Figure 8.4 StemLife: Comparison of Revenue ($m), 2013 and 2014
Figure 11.1 The Global Biobanking Market by Industry Sector: Comparison of Revenues ($bn), 2015, 2020 and 2026
Figure 11.2 Biobanking for Research by Sample Type: Comparison of Revenues ($bn), 2015, 2020 and 2026
Figure 11.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn), 2015, 2020 and 2026
Figure 11.4 Leading Regional Markets for Biobanking: Comparison of Revenues ($bn), 2015, 2020 and 2026

★調査レポート[バイオバンクの世界市場予測2016-2026]販売に関する免責事項
★調査レポート[バイオバンクの世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆